These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34886932)

  • 1. Costs of TB services in India (No 1).
    Chatterjee S; Toshniwal MN; Bhide P; Sachdeva KS; Rao R; Laurence YV; Kitson N; Cunnama L; Vassall A; Sweeney S; Baena IG
    Int J Tuberc Lung Dis; 2021 Dec; 25(12):1013-1018. PubMed ID: 34886932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating TB diagnostic costs incurred under the National Tuberculosis Elimination Programme: a costing study from Tamil Nadu, South India.
    Muniyandi M; Lavanya J; Karikalan N; Saravanan B; Senthil S; Selvaraju S; Mondal R
    Int Health; 2021 Dec; 13(6):536-544. PubMed ID: 33570132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of TB prevention and treatment in the Philippines in 2017.
    Capeding TPJ; Rosa JD; Lam H; Gaviola DG; Garfin AMC; Hontiveros C; Cunnama L; Laurence YV; Kitson N; Vassall A; Sweeney S; Garcia-Baena I
    Int J Tuberc Lung Dis; 2022 May; 26(5):392-398. PubMed ID: 35505478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and cost-effectiveness of Gene Xpert compared to smear microscopy for the diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia.
    Kaso AW; Hailu A
    PLoS One; 2021; 16(10):e0259056. PubMed ID: 34695153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
    Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
    BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bottom-up or top-down: unit cost estimation of tuberculosis diagnostic tests in India.
    Rupert S; Vassall A; Raizada N; Khaparde SD; Boehme C; Salhotra VS; Sachdeva KS; Nair SA; Hoog AH
    Int J Tuberc Lung Dis; 2017 Apr; 21(4):375-380. PubMed ID: 28284251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xpert MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for sensitive diagnosis of paediatric tuberculosis.
    Singh S; Singh A; Prajapati S; Kabra SK; Lodha R; Mukherjee A; Singh V; Hesseling AC; Grewal HM;
    BMC Microbiol; 2015 Sep; 15():191. PubMed ID: 26420261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Xpert MTB/RIF Assay for Diagnosis of Tuberculosis in Children.
    Das A; Anupurba S; Mishra OP; Banerjee T; Tripathi R
    J Trop Pediatr; 2019 Feb; 65(1):14-20. PubMed ID: 29438536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis in India.
    Little KM; Pai M; Dowdy DW
    PLoS One; 2014; 10(4):e0124525. PubMed ID: 25918999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting].
    Ozkutuk N; Surucüoglu S
    Mikrobiyol Bul; 2014 Apr; 48(2):223-32. PubMed ID: 24819260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront Xpert MTB/RIF for diagnosis of pediatric TB-Does it work? Experience from India.
    Kalra A; Parija D; Raizada N; Sachdeva KS; Rao R; Swaminathan S; Khanna A; Chopra KK; Hanif M; Singh V; Umadevi KR; Sheladia KN; Rao R; Vasundhara N; S A; A R N; Azeem A; Chhajlani V; Khurana J; Das NJ; Choudhury B; Nair SA; Mall S; Sen R; Chadha SS; Denkinger CM; Boehme C; Sarin S
    PLoS One; 2020; 15(8):e0236057. PubMed ID: 32756559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.
    Khaparde S; Raizada N; Nair SA; Denkinger C; Sachdeva KS; Paramasivan CN; Salhotra VS; Vassall A; Hoog AV
    PLoS One; 2017; 12(9):e0184270. PubMed ID: 28880875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.
    Dowdy DW; Steingart KR; Pai M
    PLoS Med; 2011 Aug; 8(8):e1001074. PubMed ID: 21857810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.